Correlation Between Inhibrx and Y MAbs

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Y MAbs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Y MAbs into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Y mAbs Therapeutics, you can compare the effects of market volatilities on Inhibrx and Y MAbs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Y MAbs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Y MAbs.

Diversification Opportunities for Inhibrx and Y MAbs

0.63
  Correlation Coefficient

Poor diversification

The 3 months correlation between Inhibrx and YMAB is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Y mAbs Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Y mAbs Therapeutics and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Y MAbs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Y mAbs Therapeutics has no effect on the direction of Inhibrx i.e., Inhibrx and Y MAbs go up and down completely randomly.

Pair Corralation between Inhibrx and Y MAbs

Given the investment horizon of 90 days Inhibrx is expected to generate 0.69 times more return on investment than Y MAbs. However, Inhibrx is 1.45 times less risky than Y MAbs. It trades about -0.09 of its potential returns per unit of risk. Y mAbs Therapeutics is currently generating about -0.1 per unit of risk. If you would invest  1,743  in Inhibrx on September 14, 2024 and sell it today you would lose (268.00) from holding Inhibrx or give up 15.38% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Inhibrx  vs.  Y mAbs Therapeutics

 Performance 
       Timeline  
Inhibrx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Y mAbs Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Y mAbs Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Inhibrx and Y MAbs Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibrx and Y MAbs

The main advantage of trading using opposite Inhibrx and Y MAbs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Y MAbs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Y MAbs will offset losses from the drop in Y MAbs' long position.
The idea behind Inhibrx and Y mAbs Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Other Complementary Tools

Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
CEOs Directory
Screen CEOs from public companies around the world